DRW Securities’s Immunome IMNM Stock Holding History

DRW Securities’s Portfolio IMNM Stock Details IMNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-24,355	Closed	-$250K	–	1441
2025 Q3	$250K	Sell	24,355 -3,744	-13%	-$37.2K	﹤0.01%	948
2025 Q2	$261K	Buy	+28,099	New	+$230K	0.01%	800

Other funds holding IMNM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

DRW Securities's IMNM Position: Q4 2025 in Review

DRW Securities sold out of Immunome (IMNM) in Q4 2025, closing a stake of 24,355 shares — an estimated $250K sold.

DRW Securities first reported a position in IMNM in Q2 2025 and held it in 2 quarters. The position peaked at $261K in Q2 2025. 182 funds tracked by Wall St. Rank hold IMNM as of Q4 2025.

DRW Securities reported no remaining Immunome position as of Q4 2025 after selling out during the quarter.
DRW Securities sold 24,355 Immunome shares in Q4 2025, an estimated $250K.
DRW Securities first reported a position in Immunome in Q2 2025 and held it in 2 quarters.
DRW Securities's Immunome position peaked at $261K in Q2 2025.
182 funds tracked by Wall St. Rank held Immunome as of Q4 2025.

Based on DRW Securities's 13F filing for Q4 2025, filed 12 Feb 2026.